Pharmacokinetics of thymosin α1 after subcutaneous injection of three different formulations in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 37, Issue 1, 1999, Pages 51-57

  Rost, K L ^a   Wierich, W ^a   Masayuki, F ^b   Tuthill, C W ^c   Horwitz, D L ^c   Herrmann, W M ^d  

^a PAREXEL INTERNATIONAL   (United States)

^b LSI MEDIENCE CORPORATION   (Japan)

^c SciClone Pharmaceuticals Inc   (United States)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Chronic hepatitis; Enzyme linked immunosorbent assay; Pharmacokinetics; Thymosin 1

Indexed keywords

THYMOSIN ALPHA1; IMMUNOLOGICAL ADJUVANT; THYMOSIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; HUMAN; HUMAN EXPERIMENT; INJECTION PAIN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION; BLOOD; COMPARATIVE STUDY; HALF LIFE TIME; INTRADERMAL DRUG ADMINISTRATION; TIME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ADULT; CROSS-OVER STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HUMANS; MALE; THYMOSIN; TIME FACTORS;

EID: 0032587499     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Andreone P, Cursaro C, Gramenzi A, Zavaglia C, Rezakovic I, Altomare E, Severini R, Franzone JS, Albano O, Ideo G, Bernardi M, Gasbarrini G 1996 A randomized controlled trial of thymosin alpha 1 versus interferon alpha treatment in patients with hepatitis B e antigen antibody - and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 24: 774-777
2. Garaci E, Rocchi G, Perroni L, D'Agostini C, Soscia F, Grelli S, Mastino A, Favalli C 1994 Combination treatment with zidovudine, thymosin alpha 1, and Interferon alpha in human immunodeficiency virus infection. Int J Clin Lab Res 24: 23-28
3. Hadden JW, Saha A, Sosa M, Haddem EM 1995 Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T lymphocyte responses of hydrocortisone-treated aged mice. Int J Immunopharmacol 17: 821-828
4. Interim Report of Phase 1 Single Rising Dose and Multiple Dose Study of Thymosin alpha 1 in Japan. Schering-Plough, K.K. Undated draft
5. Kolac C, Streichhan P, Lehr C-M 1996 Oral bioavailability of proteolytic enzymes. Eur J Pharm Biopharm 42: 222-232
6. Lopez M, Carpano S, Cavaliere R, DiLauro L, Ameglio F, Vitelli G 1994 Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol 5: 741-746
7. McClure JE, Lameris N, Wara DW, Goldstein AL 1981 Immunochemical studies on thymosin: radioimmunoassay of thymosin α1. J Immunol 128: 368-375
8. Rasi G, DiVirgilo D, Mutchnick MG, Colella F, Sinibaldi-Vallebona P, Pierimarchi P, Valli B, Garaci E 1996 Combination thymosin α1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 39: 679-683
9. Rasi G, Mutchnick MG, DiVirgilio D, Sinibaldi-Vallebona P, Pierimarchi P, Colella F 1996 Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B. J Viral Hepatitis 3:191-196
10. Schulof RS, Lloyd M, Cox J 1984 An evaluation of two different schedules of synthetic thymosin alpha 1 administration in patients with lung cancer: preliminary results. In: Goldstein A Thymic Hormones and Lymphokines. Plenum Press, New York, pp 601-613
11. Serrate S, Schulof R, Leondaridis L, Goldstein AL, Sztein MB 1987 Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol 139: 2338-2343
12. Sherman KE, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S, Davis D, Root S, Weber FL, Ishak KG, Goodman ZD 1998 Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial. Hepatology 27: 1128-1135
13. Steinijans VW, Diletti E 1983 Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 24: 127-136
14. Wang SS, Makofske R, Bach A, Mernfield RB 1980 Automated solid phase synthesis of thymosin alpha 1. Int J Peptide Protein Res 15: 1-4
15. Weller FE, Shah U, Cummings GD, Chretien PB, Mutchnick MG 1992 Serum levels of immunoreactive thymosin alpha 1 and thymosin beta 4 in large cohorts of healthy adults. Thymus 19: 45-52